Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells

Neurochemistry International

Volumn 57, Issue 5, 2010, Pages 525-529

  Chau, K Y ^a   Cooper, J M ^a   Schapira, A H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alpha synuclein; Free radicals; Mitochondria; Neuroprotection; Parkinson's disease; Rasagiline

Indexed keywords

ALPHA SYNUCLEIN; CASPASE 3; FREE RADICAL; GLUTATHIONE; PARAQUAT; RASAGILINE; SUPEROXIDE;

APOPTOSIS; ARTICLE; CELL DAMAGE; CELL DEATH; CELL LINE; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NEUROPROTECTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALPHA-SYNUCLEIN; CASPASE 3; CELL DEATH; CELL LINE; CELL SURVIVAL; DOPAMINE; ENZYME ACTIVATION; FREE RADICALS; GLUTATHIONE; HUMANS; INDANS; L-LACTATE DEHYDROGENASE; MEMBRANE POTENTIALS; MITOCHONDRIAL MEMBRANES; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARAQUAT; REACTIVE OXYGEN SPECIES;

EID: 77956232379     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.06.017     Document Type: Article

References (36)

1. Bar A.O., Amit T., Youdim M.B. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett. 2004, 355:169-172.
2. Bar-Am O., Amit T., Youdim M.B. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J. Neurochem. 2007, 103:500-508.
3. Bar-Am O., et al. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J. Neurochem. 2004, 89:1119-1125.
4. Chau K.Y., et al. Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptors. J. Neurol. Sci. 2009, 278:44-53.
5. Chen J.J., Swope D.M., Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin. Ther. 2007, 29:1825-1849.
6. Conway K.A., et al. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001, 294:1346-1349.
7. Dauer W., et al. Resistance of alpha-synuclein null mice to the Parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:14524-14529.
8. Desplats P., et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:13010-13015.
9. Fuchs J., et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007, 68:916-922.
10. Giasson B.I., et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290:985-989.
11. Kordower J.H., et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 2008, 14:504-506.
12. Li J.Y., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 2008, 14:501-503.
13. Mandel S., et al. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res. Brain Res. Rev. 2005, 48:379-387.
14. Maruyama W., et al. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci. Lett. 2003, 341:233-236.
15. Mosharov E.V., et al. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 2009, 62:218-229.
16. Norris E.H., et al. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J. Biol. Chem. 2003, 278:27230-27240.
17. Olanow C.W., et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2006, 5:1013-1020.
18. Olanow C.W., Kieburtz K., Schapira A.H. Why have we failed to achieve neuroprotection in Parkinson's disease?. Ann. Neurol. 2008, 64(Suppl. 2):S101-S110.
19. Olanow C.W., Kordower J.H. Modeling Parkinson's disease. Ann. Neurol. 2009, 66:432-436.
20. Olanow C.W., et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 2009, 361:1268-1278.
21. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 1993, 328:176-183. Parkinson Study Group.
22. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 2004, 61:561-566. Parkinson Study Group.
23. Ross O.A., et al. Genomic investigation of alpha-synuclein multiplication and Parkinsonism. Ann. Neurol. 2008, 63:743-750.
24. Schapira A.H. Science, medicine, and the future: Parkinson's disease. BMJ 1999, 318:311-314.
25. Schapira A.H. Etiology of Parkinson's disease. Neurology 2006, 66:S10-S23.
26. Schapira A.H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 2008, 7:97-109.
27. Schapira A.H. Rasagiline in neurodegeneration. Exp. Neurol. 2008, 212:255-257.
28. Schapira A.H. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology 2009, 72:S44-S50.
29. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
30. Tabrizi S.J., et al. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum. Mol. Genet. 2000, 9:2683-2689.
31. Varez-Fischer D., et al. Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid. J. Neurochem. 2008, 107:701-711.
32. Youdim M.B., et al. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol. 2001, 132:500-506.
33. Youdim M.B., et al. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann. N. Y. Acad. Sci. 2001, 939:450-458.
34. Youdim M.B., Weinstock M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol. Neurobiol. 2001, 21:555-573.
35. Youdim M.B., Maruyama W., Naoi M. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiParkinsonian drug, rasagiline. Drugs Today (Barc.) 2005, 41:369-391.
36. Youdim M.B., et al. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res. 2005, 79:172-179.